The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a promising trial or a drug that will make it to market—or crash and burn. As a penny stock with a market cap of just $600 million, Absci Corp. (NASDAQ: ABSI) falls squarely in the high-risk, high-reward category.
The company operates at the intersection of AI and biotechnology, utilizing machine learning and automation to discover and develop novel therapeutics. As this trend grows across the biotech space, Absci is on the cutting edge, giving it the potential to lead a new generation of companies creating new medicines—but the firm's technological leadership, strategic partnerships, valuation and potential for growth must be considered against its early-stage status and execution risk.
